MalDA, Accelerating Malaria Drug Discovery

TY - JOUR

T1 - MalDA, Accelerating Malaria Drug Discovery

AU - Yang, Tuo

AU - Ottilie, Sabine

AU - Istvan, Eva S.

AU - Godinez-Macias, Karla P.

AU - Lukens, Amanda K.

AU - Baragaña, Beatriz

AU - Campo, Brice

AU - Walpole, Chris

AU - Niles, Jacquin C.

AU - Chibale, Kelly

AU - Dechering, Koen J.

AU - Llinás, Manuel

AU - Lee, Marcus C. S.

AU - Kato, Nobutaka

AU - Wyllie, Susan

AU - McNamara, Case W.

AU - Gamo, Francisco Javier

AU - Burrows, Jeremy

AU - Fidock, David A.

AU - Goldberg, Daniel E.

AU - Gilbert, Ian H.

AU - Wirth, Dyann F.

AU - Winzeler, Elizabeth A.

N1 - Funding Information: The complete list of authors includes those named in the author list, as well as the members of the Malaria Drug Accelerator Consortium, which include John Okombo, Manu Vanaerschot, Charisse Flerida A. Pasaje, Krittikorn Kumpornsin, James M. Murithi, Jessica L. Bridgford, Tarrick Qahash, Edward Owen, Lauren Arendse, Kathryn Wicht, Victor Corpas Lopez, and Rachel Milne. T.Y. and S.O. are supported by grants from BMGF (OPP1054480). E.A.W. is supported by grants from the National Institutes of Health (NIH) (R01 AI152533, R01 AI152551), the BMGF (OPP1054480), and MMV. D.A.F. gratefully acknowledges funding from the MMV and the NIH (R01 AI50234, R01 AI124678). B.B, S.W. and I.H.G are supported by a Wellcome Trust Centre Award [203134/Z/16/Z]. Figures were created with BioRender.com. K.J.D. holds stock in TropIQ Health Sciences. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Copyright: © 2021 The Authors

PY - 2021/6

Y1 - 2021/6

N2 - The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories. The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process by identifying new, essential, druggable targets. In addition, it seeks to produce early lead inhibitors that may be advanced into drug candidates suitable for preclinical development and subsequent clinical testing in humans. By sharing resources, including expertise, knowledge, materials, and reagents, the consortium strives to eliminate the structural barriers often encountered in the drug discovery process. Here we discuss the mission of the consortium and its scientific achievements, including the identification of new chemically and biologically validated targets, as well as future scientific directions.

AB - The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories. The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process by identifying new, essential, druggable targets. In addition, it seeks to produce early lead inhibitors that may be advanced into drug candidates suitable for preclinical development and subsequent clinical testing in humans. By sharing resources, including expertise, knowledge, materials, and reagents, the consortium strives to eliminate the structural barriers often encountered in the drug discovery process. Here we discuss the mission of the consortium and its scientific achievements, including the identification of new chemically and biologically validated targets, as well as future scientific directions.

KW - MalDA

KW - Plasmodium falciparum

KW - drug resistance

KW - malaria

KW - target-based drug discovery

UR - https://www.scopus.com/pages/publications/85101721246

U2 - 10.1016/j.pt.2021.01.009

DO - 10.1016/j.pt.2021.01.009

M3 - Review article

C2 - 33648890

SN - 1471-4922

VL - 37

SP - 493

EP - 507

JO - Trends in Parasitology

JF - Trends in Parasitology

IS - 6

ER -